Diamyd Medical AB (publ)
STO: DMYD-B.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ulf Hannelius
- Employees
- 30
- Headquarters
- Stockholm, Sweden
- IPO year
- 2013
- Market cap
- SEK 161.3M
- Website
- https://www.diamyd.com
Loading DMYD-B…
Loading profile data…Frequently asked questions about DMYD-B
What does Diamyd Medical AB (publ) (DMYD-B.ST) do?
Diamyd Medical AB (publ) develops therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy diabetes vaccine, which is in phase IIb clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes; and Remygen, an oral regenerative and immunomodulatory drug candidate, whi...
Where does DMYD-B.ST trade?
Diamyd Medical AB (publ) (DMYD-B.ST) trades on the Stockholm Stock Exchange.
What sector is DMYD-B.ST in?
Diamyd Medical AB (publ) (DMYD-B.ST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Diamyd Medical AB (publ)?
Ulf Hannelius is the chief executive officer of Diamyd Medical AB (publ) (DMYD-B.ST).
Where is Diamyd Medical AB (publ) headquartered?
Diamyd Medical AB (publ) is headquartered in Sweden.
Does DMYD-B.ST pay a dividend?
Diamyd Medical AB (publ) (DMYD-B.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DMYD-B.ST go public?
Diamyd Medical AB (publ) (DMYD-B.ST) completed its initial public offering in 2013.